Kornitzer Capital Management Inc. KS Reduces Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Kornitzer Capital Management Inc. KS lessened its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 13.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 97,262 shares of the medical research company's stock after selling 14,500 shares during the period. Kornitzer Capital Management Inc. KS owned about 0.05% of IQVIA worth $23,048,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. 1832 Asset Management L.P. lifted its holdings in IQVIA by 472.3% in the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock valued at $96,487,000 after buying an additional 376,595 shares during the period. Renaissance Technologies LLC acquired a new stake in IQVIA during the second quarter worth approximately $70,610,000. Impax Asset Management Group plc lifted its stake in IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock valued at $344,998,000 after buying an additional 264,555 shares during the period. Canada Pension Plan Investment Board boosted its holdings in shares of IQVIA by 6.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company's stock worth $719,634,000 after buying an additional 211,653 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in shares of IQVIA by 285.1% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company's stock worth $56,783,000 after buying an additional 198,808 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IQV. Barclays cut their price objective on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Evercore ISI dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. Argus raised shares of IQVIA to a "strong-buy" rating in a research report on Wednesday, July 31st. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a research report on Tuesday. Finally, Robert W. Baird cut their price target on IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $259.13.

IQVIA Stock Performance

IQV traded down $3.57 during trading on Thursday, hitting $217.68. 1,771,527 shares of the company traded hands, compared to its average volume of 1,099,974. IQVIA Holdings Inc. has a one year low of $190.20 and a one year high of $261.73. The stock's fifty day moving average is $232.31 and its 200 day moving average is $229.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market cap of $39.51 billion, a P/E ratio of 28.57, a price-to-earnings-growth ratio of 2.15 and a beta of 1.51.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company's stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.